TippingPoint Biosciences, a San Francisco, CA-based therapeutic company focused on innovative drug discovery targeting the aberrant DNA in cancer cells, raised a Pre-Seed funding of undisclosed amount.
Backers included Pediatric Brain Tumor Foundation, Sontag Foundation, Yuvaan Tiwari Foundation, and BrightEdge.
The company intends to use the funds to expand operations and its development effrots.
Led by CEO and founder Dr. Laura Hsieh, formerly a post-doctoral researcher in Dr. Geeta Narlikar’s lab at the University of California San Francisco (UCSF), TippingPoint Biosciences is an early-stage therapeutic company with a novel drug discovery platform to identify first-in-class drugs aimed at treating diseases related to dysfunctional DNA packaging (chromatin). TippingPoint Bio develops a screening platform to enable direct targeting of the defective chromatin in disease cells without affecting healthy cells. The platform can be applied to multiple disease areas like cancer, neurodegenerative diseases and developmental disorders
FinSMEs
04/09/2024